Phreesia, Inc. (NYSE:PHR) Receives $31.00 Consensus Target Price from Analysts

Phreesia, Inc. (NYSE:PHR) has been assigned a consensus recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $31.00.

A number of equities research analysts have issued reports on the company. DA Davidson increased their price target on Phreesia from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. BMO Capital Markets began coverage on shares of Phreesia in a report on Thursday, November 13th. They issued an “outperform” rating and a $32.00 target price on the stock. KeyCorp decreased their price target on shares of Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research note on Wednesday, October 8th. Canaccord Genuity Group dropped their price objective on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, December 9th. Finally, Barclays reduced their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, December 16th.

Insiders Place Their Bets

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,241 shares of the stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $22.36, for a total value of $27,748.76. Following the transaction, the general counsel directly owned 135,737 shares in the company, valued at $3,035,079.32. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Linetsky sold 2,059 shares of the firm’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $22.36, for a total transaction of $46,039.24. Following the sale, the insider directly owned 171,829 shares in the company, valued at approximately $3,842,096.44. The trade was a 1.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 7,534 shares of company stock valued at $165,514 in the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. lifted its position in Phreesia by 2.7% during the 2nd quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock worth $400,000 after acquiring an additional 375 shares during the period. Diversified Trust Co lifted its holdings in shares of Phreesia by 1.0% during the second quarter. Diversified Trust Co now owns 45,042 shares of the company’s stock worth $1,282,000 after purchasing an additional 426 shares during the period. PNC Financial Services Group Inc. grew its position in Phreesia by 2.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 19,983 shares of the company’s stock valued at $569,000 after buying an additional 540 shares during the last quarter. Oppenheimer Asset Management Inc. increased its stake in Phreesia by 9.9% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 8,803 shares of the company’s stock valued at $251,000 after buying an additional 792 shares during the period. Finally, Alliancebernstein L.P. raised its position in Phreesia by 1.3% during the 3rd quarter. Alliancebernstein L.P. now owns 62,712 shares of the company’s stock worth $1,475,000 after buying an additional 812 shares during the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Price Performance

Phreesia stock opened at $16.30 on Thursday. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia has a 52-week low of $15.41 and a 52-week high of $32.76. The firm has a market cap of $982.43 million, a PE ratio of -162.93 and a beta of 0.61. The company’s 50 day moving average is $19.54 and its two-hundred day moving average is $24.04.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.11. The business had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company’s revenue was up 12.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.25) earnings per share. On average, research analysts expect that Phreesia will post -1.1 EPS for the current fiscal year.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.